The Biden administration is preparing to roll out a fall COVID-19 booster campaign with new bivalent vaccines, which have protection against both the original and Omicron strain of the virus. Bivalent boosters from Moderna and Pfizer have been authorized on an emergency basis. (Politico)

In a reversal, a Food and Drug Administration advisory panel has authorized an experimental ALS drug from Amylyx Pharmaceuticals. The panel previously rejected the drug in March. (NBC News)

Arcutis Biotherapeutics will acquire Ducentis BioTherapeutics in a $16 million cash and $14 million stock deal. The acquisition includes Ducentis’ lead preclinical drug, DS-234, which suppresses overactive immune responses and inflammation in dermatological diseases. (Endpoints News)

A federal judge has struck down an Affordable Care Act requirement for employers to cover HIV prevention medication. The judge argued that the requirement to cover PrEP violates the Religious Freedom Restoration Act. (Axios)
The FDA approved Revance Therapeutics’ Daxxify, which smooths facial wrinkles. The drug is expected to emerge as a major competitor to Abbvie’s Botox. (The New York Times)